BSX Boston Scientific Corporation Common Stock

NYSE · Health Care · View on SEC EDGAR ↗
$51.60
Price · Aug 19, 2026
Fundamentals as of Aug 3, 2026
52W Range
$42–$110
14% of range
Analyst Rating
BUY
38 analysts
Price Target
$63
+21% upside
P/E (TTM)
49.1
ROE
12.6%
Net Profit Margin
14.4%

About Boston Scientific Corporation Common Stock Company overview from Wikipedia

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Read more

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.

BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

History

Boston Scientific was formed on June 29, 1979, in Watertown, Massachusetts, as a holding company for the medical products company Medi-Tech, Inc., and to position the company for growth in interventional medicine. Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the Arthur D. Little think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont, Massachusetts, a venture he founded in 1965 with a business friend, Dan Singer.

In 1967 Bentov was asked by Boston Beth Israel Hospital radiologists to design a steerable, remotely controlled catheter; a series of engineering designs, polymer improvements and prototypes led to the release of a new steerable angiography catheter in 1969. That year John Abele joined the small company with an option to buy. A year later he exercised his option with Cooper Labs as a business partner, and the operation was moved – out of Bentov's lab in the basement of the rectory of a Catholic church in Belmont – to Watertown.

After a decade of steady growth, Abele met Pete Nicholas by chance in their neighborhood in Concord, Massachusetts. Their partnership hinged on Nicholas' goal to build business enterprises and Abele's predilection for the vision and potential in noninvasive surgical instrumentation; they gathered backers in the Boston banking community to buy out the Cooper Labs interest and form the new corporation.

Less than a year later Kimray Medical Associates (later Mansfield Scientific, Inc.) was acquired, adding vena cava filters and cardiac output computers to the product line. By 1982 a renovated mill building in Watertown was transformed into a manufacturing plant. Acquisitions continued, with Endo-Tech (Microvasive, Inc.: gastrointestinal and pulmonary) in 1981 and then Van-Tec (urology) in 1988, and an international presence was expanded. Mansfield Scientific, Microvasive, and Medi-Tech merged into Boston Scientific December 31, 1988.

Initial public offering (1992)

On May 19, 1992, Boston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million were offered in the U.S. and 4.7 million were offered outside the U.S. The initial offering amounted to 23% of Boston Scientific's outstanding stock.

Goldman, Sachs & Co. (lead) and PaineWebber Inc. were the underwriters and Abbott Laboratories held a 20% stake (23.5 million shares). The market capitalization was about $1.6 billion. The U.S. shares were listed on the New York Stock Exchange.

Post–IPO

From 1995 through 1997, Boston Scientific increased its technology R&D and product offerings following substantial acquisitions that included Cardiovascular Imaging Systems (intravascular ultrasound), SCIMED (cardiovascular), Vesica Medical (urology), Meadox (textile vascular prostheses), EP Technologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), Symbiosis Corporation (specialty medical product manufacture).

On November 3, 1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.

In 2001, Boston Scientific acquired Target Therapeutics (neurology) in a tax-free stock swap for about $1.1 billion, more than 10 times Target's total sales, in contrast to the usual multiple of 10 times earnings.

The Taxus Stent was approved in 2003 in Europe and other countries and, in the United States, by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.

In April 2004, the company announced that it had exercised an exclusive option to acquire Precision Vascular Systems, Inc., as part of a series of agreements between Boston Scientific and Precision Vascular in 2002, for an undisclosed sum. In June, Boston Scientific acquired Advanced Bionics Corporation for $740 million in cash, plus earn out payments. In December, Boston Scientific completed its acquisition of Advanced Stent Technologies, Inc., for $120 million payable in Boston Scientific stock, plus the possibility of future contingent payments. AST had been developing stent and stent delivery systems specifically designed to address the anatomical needs of coronary artery disease in bifurcated vessels.

In April 2005, BSC exercised an exclusive option to acquire TriVascular, Inc., for an undisclosed sum and renamed it as Boston Scientific Santa Rosa Corporation, or BSSR. TriVascular was founded in January 1998 to develop less-invasive medical devices and procedures for treating abdominal aortic aneurysms, but BSC discontinued its endovascular aortic repair (EVAR) program in 2006. BSC also announced it had exercised its option to acquire CryoVascular Systems, Inc., and its proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries. In June Boston Scientific announced that its wholly owned subsidiary, Nemo I Acquisition, Inc., had successfully acquired Salt Lake City-based Rubicon Medical Corporation, with Rubicon became a wholly owned subsidiary of Boston Scientific.

In March 2008, BSC sold BSSR to TV2 Holding Company of Santa Rosa. Terms of the sale include $30 million in cash paid at the closing to BSC and a warrant allowing BSC to purchase a minority interest in TV2.

Guidant merger

In January 2006, the company announced an offer for its longtime competitor, Guidant, for $72 per share or $25 billion. The offer, however, was rejected. On April 21, 2006, BSC acquired Guidant for $27.2 billion. Guidant was split between BSC and Abbott Laboratories. Four years later, in 2010, when moving its heart-rhythm business from its acquisition of Guidant, Boston Scientific eliminated 1300 jobs.

Post-merger

In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.

In April 2008, the company acquired CryoCor, Inc., for $1.35 per share, $17.6 million in total. Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.

2010–2020

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others. In the same month Boston Scientific acquired Asthmatx, Inc., for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.

In January 2011, Boston acquired Atritech, Inc., for $100 million, plus up to $275 million in additional potential payments. In the same month, Boston Scientific acquired Intelect Medical, Inc., for $78 million and the remaining 86% of Sadra Medical, Inc., not already owned for $193 million plus contingent payments. At the same time, the business divested its neurovascular business to Stryker Corporation for $1.5 billion.

In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved. In September, the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions. In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures. A month later, the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc.

In November 2013, Boston announced it would acquire Bard EP, the electrophysiology business of C.R. Bard, Inc. for $275 million.

In May 2014, Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc. In September, the business announced it would acquire the Interventional business of Bayer.

In March 2015, the company announced it would acquire Endo International Plc's American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments. In April, Boston announced its intention to acquire Xlumena, Inc. In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve Technologies, gaining a right to acquire the business in the future.

In July 2016, the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc. In September, Boston Scientific announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $210 million. In November, the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices. In December 2016, the business acquired a 15% stake in Neovasc, Inc., for $75 million.

In 2016, Boston Scientific acquired EndoChoice, located in Alpharetta, Georgia.

In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices. In October, Boston acquired Apama Medical Inc. for up to $300 million.

In April 2018, Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation, NxThera and Securus Medical Group, Inc., for up to $50 million. In July, Boston Scientific announced it would acquire Cryterion Medical, Inc, Veniti, Inc., in August Augmenix, Inc., and Claret Medical, Inc. In November, Boston Scientific announced it would acquire UK medical device maker BTG plc for $4.2 billion. In late December, the company announced it would acquire Millipede, Inc for $325 million, after previously investing $90 million in the company.

In May 2019, the company announced it would acquire Vertiflex, Inc., with the aim of increasing its interventional pain therapy offerings. Vertiflex principally developed treatment for lumbar spinal stenosis.

2021–present

In January 2021, Boston announced it would acquire Minneapolis-based Preventice Solutions, Inc., and its portfolio of mobile cardiac health solutions for up to $1.2 billion. In March, the business announced it would acquire the surgical business part of Lumenis Ltd. for $1 billion from an affiliate of Baring Private Equity Asia, who, in 2019, had acquired Lumenis from XIO Group. In June, the company announced it would acquire the 73% of Farapulse, Inc., it did not already own, for $295 million. Farapulse was a University of Iowa startup. In September, the business announced it would acquire Devoro Medical, Inc., and its blood clot capturing technology. Boston Scientific had been a strategic investor in Devoro since 2019. In October, the company announced it would acquire Baylis Medical Company Inc. for $1.75 billion, expanding its electrophysiology and heart product portfolios (see Frank Baylis).

In June 2022, the Boston Scientific announced it would acquire M.I.Tech Co., Ltd., of South Korea, for around $230 million. The deal was cancelled in May 2023 citing regulatory hurdles. In August, Boston announced it would acquire Obsidio, Inc.

In June 2022, Boston Scientific announced that it would invest $62.5 million in a manufacturing and supply chain facility in Johns Creek, Georgia, a suburb of Atlanta.

In September 2023, Boston Scientific acquired Relievant Medsystems, Inc. for an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

In January 2024, the company announced it would acquire Axonics, Inc. for $3.7 billion.

In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal. The deal was expected to close by yearend.

Corporate governance

Michael F. Mahoney is the current Boston Scientific chairman and chief executive officer.

Organizational culture

The journal US Black Engineer & Information Technology (USBE & IT), in its "2021 Top Supporters of HBCU Engineering," ranked BSC No. 6 among the "Top 20 Industry Supporters."

Financials

Litigation

Johnson & Johnson patent litigation

Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.

It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion-dollar trial was set for November 20, 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

Transvaginal mesh

Boston Scientific is one of several manufacturers of a medical device called transvaginal mesh, a type of surgical mesh used to treat pelvic organ prolapse. Experts concluded that the medical company had used cheap, counterfeit resin, which was both toxic and degraded when exposed to oxygen. When this was announced on 60 Minutes, Boston Scientific responded by saying the broadcast was "irresponsible and misleading," citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns." One woman, who sued in 2011, was awarded $100 million. Two operations had failed to remove all the parts of the mesh and she was still in pain. The company appealed the decision and had the amount reduced to $10M. In 2015, Boston Scientific announced it would pay $119 million to 2,970 lawsuit plaintiffs, who had been injured by the mesh. On March 23, 2021, the company agreed to pay $189 million to settle allegations that it had seriously misrepresented the risks related to the vaginal mesh. As of Jan. 27, 2021, around 54,000 lawsuits related to transvaginal meshes had been filed against Boston Scientific.

In April 2019, the FDA ordered Boston Scientific and Coloplast to remove all of their vaginal mesh products from the United States market. In 2020, Johnson & Johnson was required to pay $344 million for failing to disclose the serious product risks of its transvaginal mesh product.

NIR stent

In 2005, Boston Scientific paid $74 million to settle allegations that it had continued to sell NIR stents (flexible stents) after learning that many of them were defective. Twenty-six injuries and one death may have been caused by malfunctioning stents.

Defective defibrillators

In 2011, Guidant, a subsidiary of Boston Scientific, was criminally convicted of a failure to report defibrillator safety problems to the FDA. The company was forced to pay more than $296 million in criminal fines and had to submit to the supervision of the U.S. Probation Office for three years.

Even though Guidant knew the devices were defective, they continued to sell the defibrillators anyway. Guidant LLC had also advised its sales representatives to tell physicians that nothing was wrong with the defibrillators, and told the FDA that the proposed corrections were not being done to correct life-threatening device flaws, but were rather to improve process throughout. Not until three deaths had occurred and ten months had passed did the company reveal the defects in 2005. The directives for these wrongdoings had been implemented prior to Boston Scientific's acquisition of Guidant in 2006.

In 2013, BSC and three of its subsidiaries – Guidant LLC, Guidant Sales LLC, and Cardiac Pacemakers, Inc. – agreed to pay $30 million to settle allegations that, according to the Justice Department, between 2002 and 2005, Guidant knowingly sold defective heart devices to health care facilities that in turn implanted the devices into Medicare patients.

Bribery allegations

In 2009, Boston Scientific agreed to pay $22 million to settle allegations that its subsidiary Guidant LLC had used kickback schemes to boost sales for its pacemakers (cardiac rhythm management or CRM devices) and defibrillators (implantable cardioverter-defibrillators or ICD devices). Allegedly, Guidant paid doctors between $1,000 and $1,500 each to participate in one of its four post-studies known as RaCE ($1,500), RaCE II ($1,000), RaCE III ($1,000), and MERITS ($1,000).

Obsidio Embolic recall

In April 2024, the FDA announced a recall of Boston Scientific's device Obsidio Embolic, which is used to stop hemorrhaging and excessive bleeding. It has been found that when the device is paired with the aliquot technique, it can lead to bowel ischemia, which can mean longer hospitalization or death for patients.

Notable people

Donald Steven Baim, MD (1946–2009), served Chief Medical and Scientific Officer for Boston Scientific from 2006 until his death in 2009.

Ian Meredith, MD, PhD, AM (born 1956), was Global Chief Medical Officer and Executive Vice President from 2017 to 2023.

Ursula Burns (born 1958), who served as a Member of Boston Scientific's 13-seat Board of Directors since 2002, resigned after being named Chief Executive Officer of the Xerox Corporation, taking effect July 1, 2009, and becoming the first African-American female CEO of a Fortune 500 company.

Kristina M. Johnson (born 1957), PhD, who served as a Member of BSC's Board since May 2006, resigned in May 2009 after being confirmed by the U.S. Senate to serve as Under Secretary in the Department of Energy (see Under Secretary of Energy for Infrastructure & Under Secretary of Energy for Science and Innovation). Johnson was re-elected to BSC's board January 1, 2011, and served in that position until May 2017.

Yoshiaki Fujimori (born 1951), BSC Board Member since July 2016.

James Robert Tobin Jr. (born 1944), President & CEO of BSC from 1999 through 2009.

John Raymond Elliott "Ray" (born 1950), served as a Board Member from September 2007 to 2009, then, in July 2009, re-joined the Board and became President & CEO, a position he held until December 31, 2011. Before, he had served as Chairman of Zimmer Holdings, Inc., from August 6, 2001, to November 30, 2007, and President & CEO from March 20, 2001, to May 2007.

Headquarters and regional centers

World headquarters: Marlborough, Massachusetts

Europe headquarters: Voisins-le-Bretonneux, France

Asia Pacific headquarters: Boston Scientific Asia Pacific Pte Ltd., Singapore

U.S. Government Affairs office: Washington, D.C.

Latin America headquarters: Weston, Florida

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

BSX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$51.60
Market Cap
—
P/E (TTM)
49.1
EPS (TTM)
$1.94
Revenue (TTM)
$20.07B
Div Yield
—
ROE
12.6%
Debt/Equity
—
52W Range
$42 – $110

BSX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $20.07B
10-point trend, +139.4%
2016-12-31 → 2025-12-31
EPS $1.94
10-point trend, +676.0%
2016-12-31 → 2025-12-31
Free Cash Flow $3.66B
8-point trend, +230.4%
2017-12-31 → 2025-12-31
Margins 14.4%
8-point trend, -3.3%
2017-12-31 → 2025-12-31

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
BSX
Peer Median
P/E (TTM)
5-point trend, -20.2%
49.1
26.3

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
BSX
Peer Median
Gross Margin
5-point trend, +6.1%
69.0%
63.1%
Operating Margin
5-point trend, +2322.2%
18.0%
—
Net Profit Margin
5-point trend, +1836.1%
14.4%
15.6%
ROA
5-point trend, +2677.8%
7.0%
7.6%
ROE
5-point trend, +2471.7%
12.6%
15.0%
ROIC
5-point trend, +2459.3%
12.7%
—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
BSX
Peer Median
Current Ratio
5-point trend, -11.1%
1.6
1.7
Quick Ratio
5-point trend, -23.3%
0.4
—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
BSX
Peer Median
Revenue YoY
5-point trend, +68.9%
19.9%
—
Revenue CAGR 3Y
5-point trend, +68.9%
16.5%
—
Revenue CAGR 5Y
5-point trend, +68.9%
15.2%
—
EPS YoY
5-point trend, +181.2%
55.2%
—
Net Income YoY
5-point trend, +177.8%
56.7%
—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
BSX
Peer Median
EPS (Diluted)
5-point trend, +181.2%
$1.94
—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
BSX
Peer Median

BSX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 38 analysts
  • Strong Buy 11 28.9%
  • Buy 19 50.0%
  • Hold 8 21.1%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

29 analysts · 2026-08-19
Median target $60.00 +16.3%
Mean target $62.69 +21.5%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.03%
Period EPS Actual EPS Est Surprise
June 30, 2026 $0.86 $0.84 0.02%
March 31, 2026 $0.80 $0.79 0.01%
Dec. 31, 2025 $0.80 $0.79 0.01%
Sept. 30, 2025 $0.75 $0.72 0.03%
June 30, 2025 $0.75 $0.73 0.02%
March 31, 2025 $0.75 $0.68 0.07%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
BSX — 49.1 19.9% 14.4% 12.6% 69.0%
ABT $250.18B 33.7 5.7% 14.7% 13.1% —
ISRG $201.11B 72.0 20.5% 28.4% 16.7% 66.0%
SYK $134.44B 41.8 11.2% 12.9% 15.1% 64.0%
EW $49.50B 46.6 11.6% 17.7% 10.6% 78.0%
BDX — 25.3 8.2% 7.7% 6.5% —
IDXX $53.93B 51.7 10.4% 24.6% 69.2% 61.8%
DXCM $25.54B 31.8 15.6% 17.9% 31.4% 60.1%
GEHC — 18.0 4.8% 10.1% 22.1% 40.0%
RMD $28.11B 18.7 9.8% 26.9% 23.6% 61.1%
ZBH $28.66B 25.3 7.2% 8.6% 5.6% —

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 16
Annual Income Statement data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Cost of Revenue 12-point trend, +181.5% $6.22B $5.26B $4.34B $3.96B $3.71B $3.46B $3.12B $2.81B $2.59B $2.42B $2.17B $2.21B
Gross Profit 12-point trend, +168.0% $13.85B $11.49B $9.90B $8.73B $8.18B $6.45B $7.62B $7.01B $6.46B $5.96B $5.30B $5.17B
SG&A Expense 12-point trend, +137.3% $6.89B $5.98B $5.19B $4.52B $4.36B $3.79B $3.94B $3.57B $3.29B $3.10B $2.87B $2.90B
Operating Expenses 12-point trend, +87.2% $10.24B $8.89B $7.55B $7.08B $6.98B $6.53B $6.10B $5.50B $5.17B $5.51B $5.59B $5.47B
Operating Income 12-point trend, +1300.3% $3.61B $2.60B $2.34B $1.65B $1.20B $-80M $1.52B $1.51B $1.28B $447M $-283M $-301M
Interest Expense 12-point trend, +61.6% $349M $305M $265M $470M $341M $361M $473M $241M $229M $233M $284M $216M
Other Non-op 12-point trend, -2950.0% $-228M $-321M $-358M $-508M $218M $362M $-358M $156M $-124M $-37M $-83M $8M
Pretax Income 12-point trend, +765.0% $3.38B $2.28B $1.99B $1.14B $1.08B $-79M $687M $1.42B $933M $177M $-650M $-509M
Income Tax 12-point trend, +226.4% $493M $436M $393M $443M $36M $2M $-4.01B $-249M $828M $-170M $-411M $-390M
Net Income 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
EPS (Basic) 12-point trend, +2277.8% $1.96 $1.26 $1.08 $0.45 $0.69 $-0.08 $3.38 $1.21 $0.08 $0.26 $-0.18 $-0.09
EPS (Diluted) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
Shares (Basic) 12-point trend, +11.8% 1,480,400,000 1,471,500,000 1,453,000,000 1,430,500,000 1,422,300,000 1,416,700,000 1,391,500,000 1,381,000,000 1,370,100,000 1,357,600,000 1,341,200,000 1,324,300,000
Shares (Diluted) 12-point trend, +12.9% 1,494,500,000 1,485,900,000 1,463,500,000 1,439,700,000 1,433,800,000 1,416,700,000 1,410,600,000 1,401,400,000 1,392,700,000 1,377,200,000 1,341,200,000 1,324,300,000
EBITDA 10-point trend, +1074.8% $4.98B $3.87B · $2.79B $2.29B $1.04B $2.53B $2.40B $2.13B · $442M $424M
Balance Sheet 27
Annual Balance Sheet data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +234.8% $1.97B $414M $865M $928M $1.93B $1.73B $217M $146M $188M $196M $319M $587M
Inventory 12-point trend, +211.1% $2.94B $2.81B $2.48B $1.87B $1.61B $1.35B $1.58B $1.17B $1.08B $955M $1.02B $946M
Prepaid Expense 12-point trend, +49.0% $660M $831M $621M $731M $799M $751M $880M $921M $942M $541M $365M $443M
Other Current Assets 9-point trend, +227.2% · $831M $621M $731M $799M $751M $880M $921M · $240M $254M ·
Current Assets 12-point trend, +143.9% $8.79B $6.92B $6.51B $5.76B $6.32B $6.69B $4.70B $4.00B $3.82B $3.24B $3.47B $3.61B
PP&E (Net) 12-point trend, +167.8% $4.04B $3.29B $2.86B $2.45B $2.25B $2.08B $2.08B $1.78B $1.70B $1.63B $1.49B $1.51B
PP&E (Gross) 12-point trend, +98.8% $7.64B $6.83B $6.34B $5.73B $5.53B $5.31B $5.17B $4.74B $4.62B $4.37B $4.06B $3.85B
Accum. Depreciation 12-point trend, +54.3% $3.61B $3.53B $3.48B $3.28B $3.27B $3.22B $3.09B $2.96B $2.93B $2.73B $2.57B $2.34B
Goodwill 12-point trend, +210.0% $18.28B $17.09B $14.39B $12.92B $11.99B $9.95B $10.18B $7.91B $7.00B $6.68B $6.47B $5.90B
Intangibles 12-point trend, +25.2% $7.02B $6.68B $6.00B $5.90B $6.12B $5.92B $7.89B $6.37B $5.84B $5.88B $6.19B $5.61B
Other Non-current Assets 12-point trend, +191.2% $1.19B $1.75B $1.53B $1.50B $1.41B $1.92B $1.53B $845M $688M $666M $505M $407M
Total Assets 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Accounts Payable 12-point trend, +336.6% $1.14B $960M $942M $862M $794M $513M $542M $349M $530M $447M $209M $262M
Accrued Liabilities 12-point trend, +64.2% $3.20B $2.77B $2.65B $2.16B $2.44B $2.20B $2.11B $2.25B $2.46B $2.31B $1.97B $1.95B
Current Liabilities 12-point trend, +91.1% $5.44B $6.40B $4.93B $3.80B $4.27B $3.68B $4.87B $5.26B $5.65B $3.59B $2.43B $2.85B
Capital Leases 8-point trend, +446000000.00 $446M $401M $390M $347M $389M $401M $276M $0 · · · ·
Deferred Tax 12-point trend, -81.9% $220M $155M $134M $144M $310M $330M $595M $328M $191M $18M $735M $1.21B
Other Non-current Liabilities 12-point trend, -9.8% $2.40B $1.87B $1.97B $2.04B $2.22B $2.31B $2.63B $1.88B $2.37B $2.34B $2.97B $2.67B
Long-term Debt 4-point trend, -9.2% · · · · · · · · $3.81B $5.42B $5.65B $4.20B
Total Debt 2-point trend, -100.0% · · · · · · · · · · $0 $400M
Common Stock 12-point trend, +6.2% $17M $17M $17M $17M $17M $17M $16M $16M $16M $16M $16M $16M
Retained Earnings 12-point trend, +164.1% $5.57B $2.67B $819M $-750M $-1.39B $-2.38B $-2.25B $-6.95B $-8.39B $-8.58B $-8.93B $-8.69B
Treasury Stock 12-point trend, +31.1% $2.25B $2.25B $2.25B $2.25B $2.25B $2.25B $1.72B $1.72B $1.72B $1.72B $1.72B $1.72B
AOCI 12-point trend, -523.6% $-610M $275M $49M $269M $263M $207M $270M $33M $-59M $1M $88M $144M
Stockholders' Equity 12-point trend, +275.3% $24.23B $21.77B $19.28B $17.57B $16.62B $15.33B $13.88B $8.73B $7.01B $6.73B $6.32B $6.46B
Liabilities + Equity 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Shares Outstanding 6-point trend, +5.1% · · · · · · 1,394,922,641 1,384,581,760 1,373,496,628 1,362,104,547 1,346,647,516 1,327,451,966
Cash Flow 19
Annual Cash Flow data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
D&A 12-point trend, +88.7% $1.37B $1.27B $1.20B $1.14B $1.09B $1.12B $1.01B $894M $844M $815M $769M $725M
Stock-based Comp 12-point trend, +190.3% $299M $266M $233M $220M $194M $170M $157M $140M $127M $116M $107M $103M
Deferred Tax 12-point trend, +97.6% $-12M $-90M $73M $-7M $-142M $-85M $-4.29B $-162M $244M $-343M $-605M $-494M
Amort. of Intangibles 12-point trend, +104.8% $897M $856M $828M $803M $741M $789M $699M $599M $565M $545M $495M $438M
Restructuring 12-point trend, +46.4% $101M $16M $69M $24M $40M $52M $38M $36M $37M $28M $26M $69M
Other Non-cash 10-point trend, -101.2% $-13M $144M · $-521M $-316M $382M $256M $-2.23B $107M · $568M $1.05B
Operating Cash Flow 12-point trend, +257.3% $4.53B $3.44B $2.50B $1.53B $1.87B $1.51B $1.84B $310M $1.43B $1.18B $691M $1.27B
CapEx 12-point trend, +238.2% $876M $790M $711M $588M $554M $376M $461M $316M $319M $376M $247M $259M
Investing Cash Flow 12-point trend, -254.4% $-2.64B $-5.69B $-2.57B $-2.01B $-1.60B $-411M $-5.04B $-1.92B $-1.01B $-887M $-2.19B $-745M
Net Debt Issued 5-point trend, -3560000000.00 · · · · · · $-3.56B $-602M $-1.00B · $-1.15B $0
Stock Issued 9-point trend, -100.0% · · · $0 $0 $975M $0 $0 $85M $111M $114M $60M
Stock Repurchased 8-point trend, -100.0% · · · $0 $0 $535M $0 $0 · $0 $0 $125M
Net Stock Activity 8-point trend, +100.0% · · · $0 $0 $440M $123M $101M $85M · $114M $-65M
Dividends Paid 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·
Financing Cash Flow 12-point trend, -163.3% $-395M $1.81B $5M $-548M $-95M $293M $2.97B $1.43B $110M $-206M $1.28B $-150M
Net Change in Cash 11-point trend, +316.5% $1.54B $-450M $-70M $-1.04B $173M $1.39B $-222M $-188M · $-123M $-268M $370M
Taxes Paid $561M · · · · · · · · · · ·
Free Cash Flow 10-point trend, +262.2% $3.66B $2.65B · $938M $1.32B $1.13B $1.38B $-6M $1.11B · $353M $1.01B
Levered FCF 10-point trend, +250.2% $3.36B $2.40B · $650M $986M $762M $-1.86B $-289M $1.08B · $249M $960M
Profitability 8
Annual Profitability data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Gross Margin 10-point trend, -0.4% 69.0% 68.6% · 68.8% 68.8% 65.0% 71.0% 71.4% 71.3% · 65.7% 69.3%
Operating Margin 10-point trend, +546.7% 18.0% 15.5% · 13.0% 10.1% -0.81% 14.1% 15.3% 14.2% · -4.0% -4.0%
Net Margin 10-point trend, +1006.3% 14.4% 11.0% · 5.5% 8.8% -0.83% 43.8% 17.0% 1.1% · -3.0% -1.6%
Pretax Margin 10-point trend, +347.2% 16.9% 13.6% · 9.0% 9.0% -0.80% 6.4% 14.5% 10.3% · -8.1% -6.8%
EBITDA Margin 10-point trend, +336.8% 24.8% 23.1% · 22.0% 19.3% 10.5% 23.6% 24.4% 23.5% · 5.5% 5.7%
ROA 10-point trend, +1080.3% 7.0% 5.0% · 2.2% 3.3% -0.27% 18.2% 8.3% 0.56% · -1.4% -0.71%
ROE 10-point trend, +786.9% 12.6% 8.7% · 4.0% 6.3% -0.53% 41.6% 21.2% 1.5% · -3.7% -1.8%
ROIC 10-point trend, +1336.9% 12.7% 9.7% · 5.7% 7.0% -0.54% 74.8% 20.3% 2.1% · -1.9% -1.0%
Liquidity & Solvency 4
Annual Liquidity & Solvency data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 10-point trend, +27.6% 1.6 1.1 · 1.5 1.5 1.8 1.0 0.8 0.7 · 1.4 1.3
Quick Ratio 10-point trend, +75.1% 0.4 0.1 · 0.2 0.5 0.5 0.0 0.0 0.0 · 0.1 0.2
Debt / Equity 2-point trend, -100.0% · · · · · · · · · · 0.0 0.1
Interest Coverage 10-point trend, +842.9% 10.4 8.5 · 3.5 3.5 -0.2 3.2 6.2 5.6 · -1.2 -1.4
Efficiency 2
Annual Efficiency data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 10-point trend, +8.9% 0.5 0.4 · 0.4 0.4 0.3 0.4 0.5 0.5 · 0.5 0.4
Inventory Turnover 10-point trend, -9.8% 2.2 2.0 · 2.3 2.5 2.4 2.3 2.5 2.6 · 2.2 2.4
Per Share 5
Annual Per Share data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share 5-point trend, +104.5% · · · · · · $9.95 $6.30 $5.11 · $4.69 $4.86
Revenue / Share 10-point trend, +138.4% $13.43 $11.27 · $8.81 $8.29 $7.00 $7.61 $7.01 $6.50 · $6.02 $5.63
Cash Flow / Share 10-point trend, +216.6% $3.03 $2.31 · $1.06 $1.30 $1.06 $1.30 $0.22 $1.02 · $0.45 $0.96
Cash / Share 5-point trend, -64.8% · · · · · · $0.16 $0.11 $0.14 · $0.24 $0.44
EPS (TTM) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
Growth Rates 7
Annual Growth Rates data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -0.3% 19.9% 17.6% 12.3% 6.7% 19.9% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +28.9% 16.5% 12.1% 12.8% · · · · · · · · ·
Revenue CAGR 5Y 15.2% · · · · · · · · · · ·
EPS YoY 4-point trend, +258.7% 55.2% 16.8% 137.8% -34.8% · · · · · · · ·
EPS CAGR 3Y 2-point trend, +186.5% 62.7% 21.9% · · · · · · · · · ·
Net Income YoY 4-point trend, +272.0% 56.7% 16.0% 128.1% -33.0% · · · · · · · ·
Net Income CAGR 3Y 2-point trend, +188.1% 60.6% 21.0% · · · · · · · · · ·
Valuation (TTM) 16
Annual Valuation (TTM) data for BSX
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Net Income TTM 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
Market Cap 5-point trend, +258.6% · · · · · · $63.08B $48.93B $34.05B · $24.83B $17.59B
Enterprise Value 2-point trend, +40.9% · · · · · · · · · · $24.51B $17.40B
P/E 12-point trend, +133.4% 49.1 71.5 54.0 102.8 61.6 -449.4 13.6 29.7 309.9 86.5 -102.4 -147.2
P/S 5-point trend, +149.3% · · · · · · 5.9 5.0 3.8 · 3.3 2.4
P/B 5-point trend, +66.9% · · · · · · 4.5 5.6 4.9 · 3.9 2.7
P / Cash Flow 5-point trend, +147.9% · · · · · · 34.4 157.8 23.9 · 41.4 13.9
P / FCF 5-point trend, +163.4% · · · · · · 45.9 -8155.2 30.8 · 70.3 17.4
EV / EBITDA 2-point trend, +35.1% · · · · · · · · · · 55.5 41.0
EV / FCF 2-point trend, +303.0% · · · · · · · · · · 69.4 17.2
EV / Revenue 2-point trend, +40.6% · · · · · · · · · · 3.3 2.3
Dividend Yield Flat — no change across 2 periods · · · · · · 0.00% 0.00% · · · ·
Earnings Yield 12-point trend, +398.5% 2.0% 1.4% 1.8% 0.97% 1.6% -0.22% 7.4% 3.4% 0.32% 1.2% -0.98% -0.68%
Payout Ratio 4-point trend, +100.0% · 0.00% · 7.9% 5.3% -34.2% · · · · · ·
Annual Payout 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $20.07B$16.75B$14.24B$12.68B$11.89B
Gross Margin % 69.0%68.6%—68.8%68.8%
Operating Margin % 18.0%15.5%—13.0%10.1%
Net Income $2.89B$1.85B$1.59B$698M$1.04B
Diluted EPS $1.94$1.25$1.07$0.45$0.69
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Current Ratio 1.61.1—1.51.5
Quick Ratio 0.40.1—0.20.5
Cash Flow
2025-12-312024-12-312023-12-312022-12-312021-12-31
Free Cash Flow $3.66B$2.65B—$938M$1.32B

Latest News Recent headlines mentioning this company

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 1,695 filers · $37.7B total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
171 (-64 vs prior Q) 310 (+34 vs prior Q) 593 (-92 vs prior Q) 600 (-28 vs prior Q) +164.8M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD CAPITAL MANAGEMENT LLC $4,143,696,762 97,087,553 10.98% Shares
STATE STREET CORP $2,992,345,845 70,111,196 7.93% Shares
PRIMECAP MANAGEMENT CO/CA/ $2,156,232,608 50,520,914 5.71% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $1,271,556,448 29,792,794 3.37% Shares
FMR LLC $1,239,549,312 29,042,861 3.28% Shares
GEODE CAPITAL MANAGEMENT, LLC $1,212,072,881 28,557,132 3.21% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $994,184,207 23,293,913 2.63% Shares
NORGES BANK $903,536,838 21,170,029 2.39% Shares
TWO SIGMA INVESTMENTS, LP $826,243,102 19,359,023 2.19% Shares
Capital World Investors $717,600,310 16,812,257 1.90% Shares
JANE STREET GROUP, LLC $686,580,356 16,086,700 1.82% Call option
WELLINGTON MANAGEMENT GROUP LLP $633,296,809 14,838,257 1.68% Shares
Capital Research Global Investors $605,255,716 14,180,571 1.60% Shares
TWO SIGMA ADVISERS, LP $600,558,161 6,298,460 1.59% Shares
FARALLON CAPITAL MANAGEMENT, L.L.C. $449,044,133 10,521,184 1.19% Shares
CANADA PENSION PLAN INVESTMENT BOARD $395,319,403 9,262,404 1.05% Shares
Qube Research & Technologies Ltd $381,720,146 8,943,771 1.01% Shares
VANGUARD FIDUCIARY TRUST CO $356,182,867 8,345,428 0.94% Shares
BNP PARIBAS FINANCIAL MARKETS $325,241,617 7,620,469 0.86% Shares
MORGAN STANLEY $278,890,927 6,534,464 0.74% Shares
D. E. Shaw & Co., Inc. $254,250,351 5,957,131 0.67% Shares
MAVERICK CAPITAL LTD $253,414,762 5,937,553 0.67% Shares
Ensign Peak Advisors, Inc $251,016,744 5,881,367 0.66% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $243,577,742 3,881,717 0.65% Shares
UBS Group AG $240,594,117 5,637,163 0.64% Shares
JANE STREET GROUP, LLC $238,521,448 5,588,600 0.63% Put option
BlackRock, Inc. $234,043,121 5,483,672 0.62% Shares
LAZARD ASSET MANAGEMENT LLC $227,443,076 5,329,032 0.60% Shares
Clearbridge Investments, LLC $218,981,454 5,130,774 0.58% Shares
JARISLOWSKY, FRASER Ltd $214,082,478 2,192,794 0.57% Shares
BANK OF AMERICA CORP /DE/ $211,692,928 4,960,003 0.56% Shares
MILLENNIUM MANAGEMENT LLC $210,735,360 5,437,567 0.56% Shares
DIMENSIONAL FUND ADVISORS LP $208,893,933 4,894,422 0.55% Shares
1832 Asset Management L.P. $194,487,468 4,556,876 0.52% Shares
Holocene Advisors, LP $180,429,700 4,227,500 0.48% Call option
Swiss National Bank $178,906,024 4,191,800 0.47% Shares
JANE STREET GROUP, LLC $178,652,846 4,185,868 0.47% Shares
Assenagon Asset Management S.A. $178,127,498 4,173,559 0.47% Shares
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ $170,906,014 4,042,830 0.45% Shares
National Pension Service $168,995,643 3,959,598 0.45% Shares
Legal & General Group Plc $160,927,972 3,770,571 0.43% Shares
Mitsubishi UFJ Asset Management Co., Ltd. $154,393,705 3,617,472 0.41% Shares
Ninety One UK Ltd $149,464,716 3,501,985 0.40% Shares
Sumitomo Mitsui Trust Group, Inc. $146,301,705 3,427,875 0.39% Shares
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $144,322,114 2,299,954 0.38% Shares
Employees Provident Fund Board $143,349,316 3,358,700 0.38% Shares
Vanguard Global Advisers, LLC $142,456,877 3,337,790 0.38% Shares
VOLORIDGE INVESTMENT MANAGEMENT, LLC $139,790,914 3,275,326 0.37% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $135,035,252 3,163,900 0.36% Call option
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $134,976,349 3,162,285 0.36% Shares
Caisse de depot et placement du Quebec $133,178,416 3,120,394 0.35% Shares
Alecta Tjanstepension Omsesidigt $133,002,390 3,117,000 0.35% Shares
Mirova US LLC $132,371,081 3,101,478 0.35% Shares
BARCLAYS PLC $131,524,822 3,081,650 0.35% Shares
VANGUARD ASSET MANAGEMENT, Ltd $122,627,792 2,873,191 0.32% Shares
Public Sector Pension Investment Board $119,712,961 2,804,896 0.32% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $115,346,242 2,702,583 0.31% Shares
RHUMBLINE ADVISERS $112,753,784 2,641,843 0.30% Shares
Rathbones Group PLC $108,402,974 2,539,901 0.29% Shares
RENAISSANCE TECHNOLOGIES LLC $102,944,373 2,412,005 0.27% Shares
Temasek Holdings (Private) Ltd $102,407,502 2,399,426 0.27% Shares
Pictet Asset Management Holding SA $102,158,094 2,393,080 0.27% Shares
Unisphere Establishment $101,911,304 2,387,800 0.27% Shares
MILFORD FUNDS LTD $92,593,577 2,169,484 0.25% Shares
ALLIANCEBERNSTEIN L.P. $91,340,092 1,455,619 0.24% Shares
HSBC HOLDINGS PLC $90,846,130 2,128,541 0.24% Shares
GOLDMAN SACHS GROUP INC $89,773,112 2,103,400 0.24% Call option
NOMURA HOLDINGS INC $88,556,732 2,074,900 0.23% Call option
Cubist Systematic Strategies, LLC $88,171,996 903,124 0.23% Shares
NEUBERGER BERMAN GROUP LLC $87,691,368 2,054,624 0.23% Shares
California Public Employees Retirement System $87,402,153 2,047,848 0.23% Shares
Phoenix Financial Ltd. $82,560,747 1,934,413 0.22% Shares
Nuveen Asset Management, LLC $76,820,023 860,054 0.20% Shares
NEW YORK STATE COMMON RETIREMENT FUND $73,919,754 1,731,953 0.20% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $73,776,648 1,728,600 0.20% Put option
FIRST MANHATTAN CO. LLC. $72,442,215 1,697,334 0.19% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $71,276,539 1,670,022 0.19% Shares
Banque Transatlantique SA $71,260,298 914,874 0.19% Shares
PRINCIPAL FINANCIAL GROUP INC $70,441,674 1,650,461 0.19% Shares
ROYAL BANK OF CANADA $70,272,000 1,646,479 0.19% Shares
Squarepoint Ops LLC $69,351,970 1,624,929 0.18% Shares
D. E. Shaw & Co., Inc. $68,616,636 1,607,700 0.18% Put option
GROUPAMA ASSET MANAGMENT $68,098,768 1,571,750 0.18% Shares
Lansforsakringar Fondforvaltning AB (publ) $67,481,689 1,581,108 0.18% Shares
Walleye Capital LLC $67,356,381 1,578,172 0.18% Shares
Squarepoint Ops LLC $66,922,240 1,568,000 0.18% Call option
VANGUARD GROUP INC $66,616,468 698,652 0.18% Shares
GOLDMAN SACHS GROUP INC $65,853,458 1,542,958 0.17% Shares
CAPITAL FUND MANAGEMENT S.A. $63,426,577 1,486,096 0.17% Shares
ORBIMED ADVISORS LLC $63,302,976 1,483,200 0.17% Shares
TUDOR INVESTMENT CORP ET AL $63,065,547 1,477,637 0.17% Shares
CAXTON ASSOCIATES LP $62,622,699 701,105 0.17% Shares
ENVESTNET ASSET MANAGEMENT INC $62,259,456 1,458,786 0.16% Shares
AVIVA PLC $61,094,158 1,431,447 0.16% Shares
Navera Investment Management Ltd. $60,925,063 1,427,592 0.16% Shares
Connor, Clark & Lunn Investment Management Ltd. $60,808,373 1,424,751 0.16% Shares
JONES FINANCIAL COMPANIES LLLP $56,948,391 1,287,551 0.15% Shares
MENORA MIVTACHIM HOLDINGS LTD. $56,913,780 1,333,500 0.15% Shares
Schonfeld Strategic Advisors LLC $56,634,266 1,326,951 0.15% Shares
DEERFIELD MANAGEMENT COMPANY, L.P. $56,124,200 1,315,000 0.15% Shares

Company insiders 90 insiders · 30 officers · 18 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
William Kucheman Chief Executive Officer July 31, 2012 P 112,525 0 0 $0
James R Tobin President & CEO Feb. 24, 2009 A 550,000 0 0 $0
Jeffrey D Capello EVP & Chief Financial Officer Nov. 27, 2013 S 447 0 0 $0
Paul A Laviolette COO July 1, 2008 M 63,072 0 0 $0
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology July 31, 2026 I 64,198 0 7 $-15,168,204
Karen Prange SVP&Pres, Uro & Pelvic Health March 8, 2016 S 38,395 0 0 $0
Jean Fitterer Lance SVP, Asst GC, Bus & Regions Feb. 16, 2015 M 117,174 0 0 $0
John Michael Onuscheck SVP & President, Europe Jan. 1, 2015 M 116,025 0 0 $0
Kenneth Pucel EVP, Glob Ops, Qual & Tech Feb. 28, 2014 M 128,517 0 0 $0
Otha T. Spriggs III SVP, Human Resources Sept. 7, 2012 M 12,738 0 0 $0
Lawrence R Neumann SVP, Special Projects May 10, 2012 M 77,879 0 0 $0
Brian R Burns EVP - Global Quality & Reg Aff Feb. 28, 2012 M 79,418 0 0 $0
John B. Pedersen Pres, Uro & Women's Health Feb. 16, 2012 M 3,233 0 0 $0
Stephen F Moreci SVP, Global Sales Operations July 1, 2011 M 37,362 0 0 $0
Sam R Leno EVP & Chief Operations Officer June 6, 2011 M 432,240 0 0 $0
Fred Colen EVP & Chief Technology Officer May 10, 2010 M 72,497 0 0 $0
James Gilbert EVP, Strategy & Business Dev Feb. 26, 2010 A 67,613 0 0 $0
David W Mcfaul SVP, International Feb. 12, 2010 M 41,426 0 0 $0
Donovan Paul SVP, Corporate Communications Feb. 12, 2010 M 33,103 0 0 $0
William F Mcconnell JR SVP, Administration CRM July 24, 2009 M 55,204 0 0 $0
Donald S Baim EVP, Chief Med. & Sci. Officer July 10, 2009 M 51,756 0 0 $0
Lucia Luce Quinn Exec. Vice President-HR July 1, 2009 M 49,809 0 0 $0
Paul W Sandman EVP and General Counsel Feb. 29, 2008 M 66,846 0 0 $0
Jeffrey H Goodman SVP, International July 1, 2007 M 10,460 0 0 $0
Lawrence C Best EVP July 1, 2007 F 242,189 0 0 $0
Mark C Bartell SVP Global Sales/Mkt CRM May 25, 2007 M 1,812 0 0 $0
Mary E Russell SVP and CMO Jan. 3, 2006 D 4,706 0 0 $0
James H Taylor JR Sr. VP, Operations Feb. 9, 2005 M 9,360 0 0 $0
Dennis A Ocwieja SVP, Regulatory Jan. 3, 2005 A — 0 0 $0
Robert G Maclean SVP, HR Jan. 3, 2005 A 36,502 0 0 $0
Edward J Ludwig Director July 31, 2026 P 30,359 2 0 $430,314
JOHNSON KRISTINA M Director May 3, 2016 A 8,494 0 0 $0
Nicholas J Nicholas JR Director April 1, 2016 A 0 0 0 $0
NICHOLAS PETER M Director April 1, 2016 A 3,486,965 0 0 $0
Ernest Mario Director Nov. 16, 2015 S 86,032 0 0 $0
Uwe E Reinhardt Director Oct. 31, 2014 A 159,379 0 0 $0
Bruce L Byrnes Director Oct. 31, 2014 A 112,097 0 0 $0
Katharine T Bartlett Director May 7, 2013 A 52,464 0 0 $0
John Raymond Elliott Director Feb. 27, 2012 A 603,676 0 0 $0
Ray J Groves Director March 31, 2011 A 1,000 0 0 $0
Marye Anne Fox Director May 11, 2010 A 21,111 0 0 $0
John E Pepper Director March 31, 2010 A 58,807 0 0 $0
Ursula M Burns Director May 5, 2009 A 32,001 0 0 $0
Warren B Rudman Director May 5, 2009 A — 0 0 $0
Nancy Ann Deparle Director May 6, 2008 A 13,886 0 0 $0
Joel Lawrence Fleishman Director May 6, 2008 A 125,691 0 0 $0
PROMERICA LP 10% owner Aug. 7, 2007 J 54,635,185 0 0 $0
Emily Woodworth — Aug. 11, 2026 I 2,930 0 0 $0
Jonathan Monson — Aug. 10, 2026 I 9,908 0 0 $0
David C Habiger — Aug. 5, 2026 P 17,160 5 0 $407,941

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 7 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Boston Scientific Corporation, Boston Scientific Scimed, Inc. April 25, 2008 — Initial filing M&A / sale SEC
GUIDANT CORPORATION ( Feb. 3, 2006 — Initial filing — SEC
Undisclosed reporting person Feb. 14, 2003 — Initial filing — SEC
Undisclosed reporting person Feb. 14, 2003 — Initial filing — SEC
Undisclosed reporting person June 27, 2002 — Initial filing — SEC
Undisclosed reporting person May 23, 2002 — Initial filing M&A / sale SEC
Undisclosed reporting person July 9, 2001 — Initial filing M&A / sale SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 202 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IHI · iShares Trust 4.21% 2,859,807 SH Aug. 8, 2026 Daily
GDOC · Goldman Sachs ETF Trust 3.78% 15,740 NS May 31, 2026 N-PORT
AGNG · Global X Funds 2.44% 41,335 NS May 31, 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2.04% 3,946 NS April 30, 2026 N-PORT
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.68% 15,586 NS April 30, 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1.62% 60,302 SH Aug. 8, 2026 Daily
RSPH · Invesco Exchange-Traded Fund Trust 1.54% 245,177 SH Aug. 8, 2026 Daily
RUNN · Strategic Trust 1.54% 109,930 NS May 31, 2026 N-PORT
FMED · Fidelity Covington Trust 1.44% 12,185 NS May 31, 2026 N-PORT
HRTS · Tema ETF Trust 1.42% 15,285 NS May 31, 2026 N-PORT
SPGP · Invesco Exchange-Traded Fund Trust 1.38% 652,401 SH Aug. 8, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 1.38% 683,394 NS April 30, 2026 N-PORT
CURE · Direxion Shares ETF Trust 1.23% 29,571 NS April 30, 2026 N-PORT
IYH · iShares Trust 1.19% 887,844 SH Aug. 8, 2026 Daily
MEDI · Harbor ETF Trust 1.10% 5,252 NS April 30, 2026 N-PORT
RXL · ProShares Trust 1.04% 15,464 NS May 31, 2026 N-PORT
ESLG · Strategy Shares 0.97% 3,256 NS April 30, 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.93% 4,467,628 SH Aug. 8, 2026 Daily
IXJ · iShares Trust 0.92% 779,800 SH Aug. 8, 2026 Daily
ANEW · ProShares Trust 0.92% 1,476 NS May 31, 2026 N-PORT
GURU · Global X Funds 0.83% 8,375 NS April 30, 2026 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 0.79% 14,552 NS April 30, 2026 N-PORT
ESLV · Strategy Shares 0.66% 1,338 NS April 30, 2026 N-PORT
DTEC · ALPS ETF Trust 0.63% 9,723 NS May 31, 2026 N-PORT
ESUM · Strategy Shares 0.62% 16,531 NS April 30, 2026 N-PORT
NBGX · Neuberger Berman ETF Trust 0.60% 1,844 NS May 31, 2026 N-PORT
IIGD · Invesco Exchange-Traded Self-Indexe… 0.56% 160,000 Aug. 8, 2026 Daily
FFLC · FIDELITY COVINGTON TRUST 0.54% 105,660 NS April 30, 2026 N-PORT
ZECP · Zacks Trust 0.52% 36,519 NS May 31, 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.46% 91,846 SH Aug. 8, 2026 Daily
FFLG · FIDELITY COVINGTON TRUST 0.46% 46,964 NS April 30, 2026 N-PORT
CAPE · DoubleLine ETF Trust 0.44% 18,128 NS March 31, 2026 N-PORT
INFO · Harbor ETF Trust 0.43% 57,055 NS April 30, 2026 N-PORT
XOEF · iShares Trust 0.40% 1,861 SH Aug. 8, 2026 Daily
CATH · Global X Funds 0.40% 83,468 NS April 30, 2026 N-PORT
RCGE · EA Series Trust 0.39% 6,410 NS April 30, 2026 N-PORT
JGLO · J.P. Morgan Exchange-Traded Fund Tr… 0.39% 477,916 NS April 30, 2026 N-PORT
FWD · AB Active ETFs, Inc. 0.39% 230,737 NS May 31, 2026 N-PORT
SNPG · DBX ETF Trust 0.38% 1,068 NS May 29, 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0.37% 56,542 NS April 30, 2026 N-PORT
KRMA · Global X Funds 0.36% 8,982 NS May 31, 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0.36% 250,378 NS April 30, 2026 N-PORT
CRTC · DBX ETF Trust 0.33% 8,980 NS May 31, 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0.30% 8,609,000 Aug. 8, 2026 Daily
OEI · Listed Funds Trust 0.29% 2,132 NS April 30, 2026 N-PORT
DFUV · Dimensional ETF Trust 0.29% 713,544 NS April 30, 2026 N-PORT
MGK · VANGUARD WORLD FUND 0.28% 2,161,888 SH Aug. 8, 2026 Daily
HAPI · Harbor ETF Trust 0.28% 22,510 NS April 30, 2026 N-PORT
IWX · iShares Trust 0.27% 219,287 SH Aug. 8, 2026 Daily
IQSU · New York Life Investments ETF Trust 0.26% 14,401 NS April 30, 2026 N-PORT